Addressing Racial Disparities in Health Care

Latest News

Will Bladder Preservation Become More Common in the Future?

“For localized bladder cancer patients who have muscle invasive disease, a lot of departments across the country really do favor surgery,” Dr. Jeannie Hoffman-Censits, medical oncologist and bladder cancer specialist at Johns Hopkins, tells SurvivorNet Connect. Radiation has long been an option for selected patients who don’t have multi-focal disease, “who don’t have certain high-risk features."

Learn More

Immunotherapy is a ‘Powerful Tool’ for Treating Urothelial Cancer

Platinum-based chemotherapy remains the standard of care for the treatment of patients with metastatic urothelial cancer in the frontline setting. However, for patients who are not candidates for chemotherapy or who have PD-L1 positive tumors, immunotherapy may be considered for frontline use.

Learn More

Predicting Which Lung Cancer Patients Will Benefit From Immunotherapy

Immune checkpoint inhibitors like pembrolizumab have been a major advancement in the treatment of non-small cell lung cancer (NSCLC), but they need to be prescribed strategically to have the greatest benefit. That requires looking at the immune landscape of the cancer using PD-L1 immunohistochemistry, and specifically the Tumor Proportion Score (TPS).

Learn More

Targeted Therapies Offer Greater Precision in Advanced Lung Cancer Treatment

Lung cancer treatment is evolving from one-size-fits-all approaches to more targeted precision medicine. Understanding the molecular makeup of a patient’s tumor is essential to finding the treatment strategy that is most likely to produce a durable response.

Learn More

Could Durvalumab (Imfinzi) Improve Survival in Early-Stage NSCLC?

The PACIFIC trial revealed a clear survival benefit to giving durvalumab to patients with stage III unresectable non-small cell lung cancer (NSCLC) following chemoradiation. With the PACIFIC-4 study, researchers want to learn whether patients might benefit from this checkpoint inhibitor in the earlier stages of the disease.

Learn More

Latest Outcomes from the PACIFIC Trial Suggest Overall Survival Improvement for Lung Cancer

“The most updated outcome of the PACIFIC trial, released a couple of months ago, shows the four-year overall survival data,” says Dr. Balazs Halmos, medical oncologist and director of the Thoracic Oncology Program at Montefiore Medical Center. That, he says, is continuing to look very impressive with each year’s update.

Learn More

The PACIFIC Trial Marks Major Breakthrough in Stage III Lung Cancer Treatment

Nearly one-third of patients with non-small cell lung cancer (NSCLC) present at stage III, most with unresectable tumors. Treatments up to now have had limited success with these patients, who have faced a median survival time of approximately two years. Thanks to durvalumab (brand name: Imfinzi), the outlook is finally looking up.

Learn More

Which BTK Inhibitor is Best Upfront for CLL?

Ibrutinib was once the only bruton tyrosine kinase (BTK) inhibitor. Now that acalabrutinib (brand name: Calquence) is available, you have a decision to make when choosing an upfront therapy for your chronic lymphocytic leukemia (CLL) patients. Which of these two drugs is best?

Learn More